Haitong leads Orig3n's series B

Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B round led by Haitong International. Orig3n did not disclose how much it raised in the initial close; however, it did say it has raised over $50 million since its founding, including a $12.5 million series A co-led by Hatteras Venture Partners and Syno Capital in 2015.

Orig3n is developing allogeneic cell therapies using a bank of "superdonor" cells that could be used to treat wide swaths of the population with little risk of rejection by the immune system (see "Superdonor Squad")...